IVD Market Exceeds $60BN: New Report

The global IVD market is currently 60.5 billion dollars, according to Kalorama Information's recently released report on in vitro diagnostic (IVD) test markets.  Kalorama published our tenth edition of its study, The World Market for In Vitro Diagnostic Tests, available at  http://bit.ly/2auqUhm   After exhaustive study, the report says IVD will grow but in a complex pattern that involves challenges to growth in traditional categories and reliable large markets combined with opportunities in novel tests and growth nations.

Envisioning an Essential Diagnostics List (EDL) and Its IVD Market Impact

Kalorama Information offers relevant market research in the areas of molecular point-of-care (POC) diagnostics, traditional POC diagnostics, and physician office laboratory (POL) test markets. Market information in this post was drawn from the associated reports.

In a recent article of the New England Journal of Medicine (NEJM), health and medical experts convincingly argued for the establishment of an Essential Diagnostics List (EDL) modeled on the existing Essential Medicines List (EML). Effective use of essential medicines, including stewardship of distributed antibiotics, would be encouraged through the equal availability of diagnostics. In this post, Kalorama Information identified several core EDL test categories outlined by the NEJM article’s authors that are represented by currently marketed physician office laboratory (POL) and point-of-care (POC) diagnostics. While the potential to address future EDL-driven markets through existing IVD products exists, significant cost improvements will be necessary.

U.S. Hospitals Leverage New IVD Products in the Fight Against Critical Inpatient Infections (AACC 2016)

This blog post continues Kalorama Information’s coverage of the 2016 AACC Annual Meeting in Philadelphia. Additional coverage of trends in the U.S. IVD market as well as segment market sizes and projections are available with Kalorama’s recent market research report.

With mounting cost pressures on U.S. labs and the growing accountability of diagnostics in critical patient episodes, vendors at the 2016 Annual Meeting of the American Association of Clinical Chemistry (AACC) emphasized solutions that addressed lab efficiency and mitigation of added healthcare costs. Test and workflow automation solutions at the AACC expo in Philadelphia were reviewed in a previous blog post as relevant tools for improving lab cost efficiency. Diagnostics are also crucial tools for hospitals to avoid payment penalties resulting from poor performance or non-compliance with care standards related to hospital-acquired infections (HAIs) and sepsis.

At AACC 2016, Lab Testing Set to Move Forward Through Test and Workflow Automation

Proceedings at AACC’s Annual Meeting were notably charged in one way: the proliferation of coffee stands at vendor booths across the expo floor. Vendor demonstrations matched pace as several IVD vendors put their automated testing solutions front and center for speedy sample management and reduced turnaround times. While media attention gravitated to Theranos’ Monday presentation, attendees at Philadelphia were preoccupied with addressing the present challenges of laboratory medicine.

Retail Clinics an Evident Focus at AACC as #1 IVD Company Presents

As Kalorama continues to cover the American Association of Clinical Chemistry in Philadelphia on Tuesday, we are tempted to say 'the Empire Strikes back,"  While Monday's focus was controversial start-up Theranos, on Tuesday major vendors of the $60 billion-plus in vitro diagnostic industry unveiled their new products, enhancements and plans for existing marketed or in-development devices with a clear pathway for FDA or CE Mark.  Kalorama conducted meetings with top-tier vendors and growth companies and noted new product advances that will be part of our reports.


Subscribe to Kalorama Information Home RSS